Evidence map›Paper›PMID 41488352›Full record

ArticleiScience2025

Nouveau benzo-mimetics of 17R-Resolvin D2 are potent resolution agonists for inflammation.

Charles N Serhan, Nan Chiang, Mélissa Simard, Robert Nshimiyimana, Ana R Rodriguez, Seok Joon Mun, Daniel Irimia, Bernd W Spur

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Charles N SerhanCenter for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Nan ChiangCenter for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Mélissa SimardCenter for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Robert NshimiyimanaCenter for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Ana R RodriguezDepartment of Cell and Molecular Biology, Virtua Health College of Medicine & Life Sciences of Rowan University, Stratford, NJ 08084, USA.
Seok Joon MunCenter for Engineering in Medicine and Surgery, Massachusetts General Hospital, Harvard School of Medicine, Shriners Children's Boston, Boston, MA 02129, USA.
Daniel IrimiaCenter for Engineering in Medicine and Surgery, Massachusetts General Hospital, Harvard School of Medicine, Shriners Children's Boston, Boston, MA 02129, USA.
Bernd W SpurDepartment of Cell and Molecular Biology, Virtua Health College of Medicine & Life Sciences of Rowan University, Stratford, NJ 08084, USA.

Funding

Evaluating Resolution Mechanisms for Infectious InflammationR35GM139430 · NIGMS · BRIGHAM AND WOMEN'S HOSPITAL · PI SERHAN, CHARLES NICHOLAS · 2021 to 2025
$3.6M
In vivo Monitoring of Neutrophil Function in Patients after Stem Cell TransplantR01AI176658 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel Irimia, Charles P. Lin · 2023 to 2026
$3.2M
NIAID NIH HHS R01 AI176658NIGMS NIH HHS R35 GM139430
6 · The paper itself

Abstract

The acute inflammatory response is a highly coordinated protective process governed by a superfamily of mediators termed specialized proresolving mediators. This includes the recently uncovered 17R-Resolvin D2 (17R-RvD2). We report 17R-RvD2 is rapidly metabolized and locally inactivated by human macrophages. An analog was prepared in a stereospecific synthesis. This benzo-17R-RvD2 resists rapid enzymatic inactivation and shared 17R-RvD2's pro-resolving actions enhancing human macrophage efferocytosis (pico-nanomolar). In peritonitis, benzo-17R-RvD2 (1 ng/mouse; 2.7 pmol) limited neutrophil infiltration >70%, reduced tumor necrosis factor alpha (TNF-α), and increased interleukin-1 (IL-1) receptor antagonist. The analog (1 nM) also enhanced >50%

Indexed as

Biological sciencesImmunologyNatural sciences

Identifiers

PMID41488352
PMCPMC12757561

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.